NA
NVAX icon

Navellier & Associates’s Novavax NVAX Stock Holding History

Navellier & Associates’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,557
Closed -$645K – 332
2021
Q1 		$645K Buy
3,557
+275
+8% +$54.8K 0.12% 151
2020
Q4 		$366K Buy
3,282
+417
+15% +$44.3K 0.07% 201
2020
Q3 		$310K Buy
+2,865
New +$349K 0.07% 183

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Navellier & Associates's NVAX Position: Q2 2021 in Review

Navellier & Associates sold out of Novavax (NVAX) in Q2 2021, closing a stake of 3,557 shares — an estimated $645K sold.

Navellier & Associates first reported a position in NVAX in Q3 2020 and held it in 3 quarters. The position peaked at $645K in Q1 2021. 407 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

  • Navellier & Associates reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
  • Navellier & Associates sold 3,557 Novavax shares in Q2 2021, an estimated $645K.
  • Navellier & Associates first reported a position in Novavax in Q3 2020 and held it in 3 quarters.
  • Navellier & Associates's Novavax position peaked at $645K in Q1 2021.
  • 407 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Navellier & Associates's 13F filing for Q2 2021, filed 9 Aug 2021.